Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Recent advancements in Alzheimer disease (AD) research have provided renewed hope for patients and practitioners. Researchers have gained a better understanding of AD's underlying causes, leading to the development of new treatments targeting the disease process, not just symptoms. Three drugs—lecanemab, donanemab, and aducanumab (being discontinued)— have received FDA approval for treating AD. Designing and conducting clinical trials for AD remains complex and expensive. Overcoming hurdles in trial design and ensuring wider access to these treatments will be crucial in the fight against this devastating disease.

Read More On The Topic Here

A new oral drug, valiltramiprosate (ALZ-801), is showing promise in treating AD, especially for patients with a high risk due to their genetics. In a recent phase 2 trial, ALZ-801 demonstrated positive results in reducing harmful protein buildup in the brain, preserving brain volume, and improving cognitive function. This oral treatment offers potential benefits for patients who may not be suitable for infusion-based therapies. Currently in phase 3 development, ALZ-801 could be a significant advancement in the fight against AD.

Read More On This Topic Here